Compare PBH & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PBH | NVCR |
|---|---|---|
| Founded | 1996 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.0B |
| IPO Year | 2004 | 2015 |
| Metric | PBH | NVCR |
|---|---|---|
| Price | $46.84 | $14.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $75.33 | $28.08 |
| AVG Volume (30 Days) | 621.9K | ★ 1.4M |
| Earning Date | 05-08-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.79 |
| EPS | ★ 3.91 | N/A |
| Revenue | ★ $975,777,000.00 | $655,353,000.00 |
| Revenue This Year | N/A | $7.72 |
| Revenue Next Year | $4.31 | $6.74 |
| P/E Ratio | $12.03 | ★ N/A |
| Revenue Growth | ★ 36.77 | 8.28 |
| 52 Week Low | $42.62 | $9.82 |
| 52 Week High | $85.29 | $18.92 |
| Indicator | PBH | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 41.50 | 36.40 |
| Support Level | $44.51 | $12.66 |
| Resistance Level | $49.51 | $15.46 |
| Average True Range (ATR) | 1.77 | 1.04 |
| MACD | 0.28 | -0.28 |
| Stochastic Oscillator | 40.29 | 5.54 |
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.